Figure 1

Testing the anti-androgen response of the PCSD1 prostate cancer xenograft model in bone versus sub-cutaneous niches. A.) Rag2 ^−/− ;γ _c ^−/− mice were injected with PCSD1 xenograft tumor cells either intra-femorally (IF) or sub-cutaneously (SC) then treated at 5 weeks post-transplantation with bicalutamide or vehicle control for 18 days, B.) Changes in total body weights were equivalent in all treatment groups. Mice were weighed biweekly (SC) and weekly (IF); Vehicle control (blue line, SC n = 4 mice, IF n = 5), Bicalutamide 50 mg/kg/day, (red line, SC n = 5, IF n = 5). Differences in mouse weights were not statistically significant (Mann Whitney test, p = 0.095), Error bars denote standard error. C.) In vivo bioluminescent imaging (IVIS) of PCSD1 tumors which stably expressed GFP-luciferase: SC (left panel) and IF tumors (right panel) at the end of treatment with vehicle and bicalutamide demonstrated preferential castrate-resistance of the PCSD1 tumors in the bone niche. In all the figures, results of vehicle treatment are represented in blue and bicalutamide treatment are represented in red.